-
1Academic Journal
Authors: M. S. Brose, Yu. Panaseykin, B. Konda, C. De la Fouchardiere, B. G.M. Hughes, A. G. Gianoukakis, Y. J. Park, I. Romanov, M. K. Krzyzanowska, S. Leboulleux, T. A. Binder, C. Dutcus, R. Xie, M. H. Taylor
Source: Опухоли головы и шеи, Vol 12, Iss 1, Pp 86-98 (2022)
-
2Academic Journal
Authors: Yakovlev, P.H.
Source: Practical oncology; Том 2, № 1 (2019); 8-13
Практическая онкология-Praktična onkologìâ; Том 2, № 1 (2019); 8-13
Практична онкологія-Praktična onkologìâ; Том 2, № 1 (2019); 8-13Subject Terms: metastatic clear cell carcinoma, targeted therapy, tyrosine kinase inhibitor, vascular endothelial growth factor receptor inhibitor, survival rate, метастатический светлоклеточный рак почки, таргетная терапия, ингибитор тирозинкиназ, ингибитор VEGFR, выживаемость, метастатичний світлоклітинний рак нирки, таргетна терапія, інгібітор тирозинкіназ, інгібітор VEGFR, виживаність, 3. Good health
File Description: application/pdf
-
3Academic Journal
Authors: B. Ya. Alekseev, A. D. Kaprin, G. P. Kolesnikov, A. A. Mukhomed’yarova, E. I. Konopleva, A. S. Kalpinskiy, Б. Я. Алексеев, А. Д. Каприн, Г. П. Колесников, А. А. Мухомедьярова, Е. И. Коноплева, А. С. Калпинский
Contributors: Eisai Co., Ltd., Компания «Эйсай»
Source: Cancer Urology; Том 14, № 3 (2018); 25-36 ; Онкоурология; Том 14, № 3 (2018); 25-36 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-3
Subject Terms: ингибитор тирозинкиназ, lenvatinib, metastatic renal cell carcinoma, targeted therapy, tyrosine kinase inhibitor, ленватиниб, метастатический почечно-клеточный рак, таргетная терапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/879/782; International Agency for Research on Cancer. The GLOBOCAN project: cancer incidence and mortality worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.; Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2016. 250 с.; Ljungberg B., Albiges L., Bensalah K. et al. EAU Guidelines on renal cell carcinoma. Available at: http://uroweb.org/guideline/renal-cell-carcinoma/.; National Comprehensive Cancer Network, Inc. The NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer. V.4.2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf April 23, 2018.; Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(suppl 5): 58–68. DOI:10.1093/annonc/mdw328. PMID: 27664262.; Клинические рекомендации по лечению рака паренхимы почки у взрослых Министерства здравоохранения Российской Федерации, версия 2017 г. Доступно по: http://cr.rosminzdrav.ru/#!/schema/87.; Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007;356(2):115–24. DOI:10.1056/NEJ-Moa065044. PMID: 17215529.; Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8. DOI:10.1200/JCO.2009.23.9764. PMID: 20100962.; Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103–11. DOI:10.1016/S0140-6736(07)61904-7. PMID: 18156031.; Rini B.I., Halabi S., Rosenberg J.E. at al. Phase III trial bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137–43. DOI:10.1200/JCO.2009.26.5561. PMID: 20368558.; Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon-alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584–90. DOI:10.1200/JCO.2008.20.1293. PMID: 19487381.; Escudier B., Bellmunt J., Negrier S. et al. Phase III trial bevacizumab plus interferon alfa in patients with metastatic renal cell carcinoma (AVOREN): final results of overall survival. J Clin Oncol 2010;28(13):2144–50. DOI:10.1200/JCO.2009.26.7849. PMID: 20368553.; Sternberg C.N., Hawkins R.E., Wagstaff J. et al. A randomized, double-blind, phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6):1287–96. DOI:10.1016/j.ejca.2012.12.010. PMID: 23321547.; Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.; Negrier S. Temsirolimus in metastatic renal cell carcinoma. Ann Onc 2008;19(8): 1369–70.; Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449–56. DOI:10.1016/S0140-6736(08)61039-9. PMID: 18653228.; Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931–9. DOI:10.1016/S0140-6736(11)61613-9. PMID: 22056247.; Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803–13. DOI:10.1056/NEJ-Moa1510665. PMID: 26406148.; Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1814–23. DOI:10.1056/NEJ-Moa1510016. PMID: 26406150.; Инструкция по применению лекарственного препарата для медицинского применения Ленвима. РУ № ЛП 003398. Дата регистрации 29.12.2015 (с изменениями от 06.12.2016).; Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16(15):1473–82. DOI:10.1016/S1470-2045(15)00290-9. PMID: 26482279.; Motzer R.J., Hutson T.E., Ren M. et al. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol 2016;17(1):e4–5. DOI:10.1016/S1470-2045(15)00543-4. PMID: 26758760.; Grande E., Martínez-Sáez O., Gajate-Borau P., Alonso-Gordoa T. Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. World J Clin Oncol 2017;8(2):100–5. DOI:10.5306/wjco.v8. i2.100. PMID: 28439491.; https://oncourology.abvpress.ru/oncur/article/view/879
-
4Academic Journal
Authors: B. Ya. Alekseev, A. S. Kalpinskiy, A. A. Mukhomed’yarova, K. M. Nyushko, A. D. Kaprin, Б. Я. Алексеев, А. С. Калпинский, А. А. Мухомедьярова, К. М. Нюшко, А. Д. Каприн
Source: Cancer Urology; Том 13, № 2 (2017); 49-55 ; Онкоурология; Том 13, № 2 (2017); 49-55 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2017-13-2
Subject Terms: торизел, targeted therapy, tyrosine-kinase inhibitor, poor prognosis, temsirolimus, torisel, таргетная терапия, ингибитор тирозинкиназ, неблагоприятный прогноз, темсиролимус
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/687/658; International Agency for Research on Cancer. The GLOBOCAN project: cancer incidence and mortality worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.; Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с. [Malignant tumors in Russia in 2015 (morbidity and fatality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 p. (In Russ.)].; Janzen N.K., Kim H.L., Figlin R.A. et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30(4):843–52. PMID: 14680319.; Motzer R.J., Masumdar M., Bacic J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530–40. DOI:10.1200/JCO.1999.17.8.2530. PMID: 10561319.; Motzer R.J., Bacik J., Murphy B.A. et al. Interferon alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289–96. DOI:10.1200/JCO.2002.20.1.289. PMID: 11773181.; Heng D.Y., Xie W., Regan M.M. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27(34):5794–9. DOI:10.1200/JCO.2008.21.4809. PMID: 19826129.; Heng D.Y., Xie W., Regan M.M. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013;14(2):141–8. DOI:10.1016/S1470-2045(12)70559-4. PMID: 23312463.; Motzer R.J., Bacik J., Schwartz L.H. et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454–63. DOI:10.1200/JCO.2004.06.132. PMID: 14752067.; Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl 3):49–56. DOI:10.1093/annonc/mdu259. PMID: 25210086.; Ljungberg B., Bensalah K., Bex A. et al. Guidelines on renal cell carcinoma. European Association of Urology, 2015. Available at: http://uroweb.org.; Santoni M., De Tursi M., Felici A. et al. Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Rev Anticancer Ther 2013;13(6):697–709. DOI:10.1586/era.13.52. PMID: 23773104.; Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81. DOI:10.1056/NEJMoa066838. PMID: 17538086.; Negrier S. Temsirolimus in metastatic renal cell carcinoma. Ann Oncol 2008;19(8):1369–70. DOI:10.1093/annonc/mdn373. PMID: 18504249.; Logan T., McDermott D., Dutcher J. et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features [abstract 5050]. J Clin Oncol 2008. ASCO Annual Meeting Proceedings 2008;26 part I, suppl 15S:262.; Dutcher J.P., de Souza P., McDermott C. et al. Effect of temsirolimus versus interferon alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26(2):202–9. DOI:10.1007/s12032-009-9177-0. PMID: 19229667.; Kapoor A., Figlin R.A. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 2009;115(16):3618–30. DOI:10.1002/cncr.24409. PMID: 19479976.; Bellmunt J., Szczylik C., Feingold J. et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19(8):1387–92. DOI:10.1093/annonc/mdn066. PMID: 18385198.; Hudes G.R., Berkenblit A., Feingold J. et al. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol 2009;36(Suppl 3):S26–36. DOI:10.1053/j.seminoncol.2009.10.013. PMID: 19963097.; Schrader A.J., Seseke S., Keil C. et al. Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer. Eur Urol 2014;66(2):275–81. DOI:10.1016/j.eururo.2013.08.055. PMID: 24012472.; Negrier S., Gravis G., Perol D. et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised Phase 2 trial. Lancet Oncol 2011;12(7):673–80. DOI:10.1016/S1470-2045(11)70124-3. PMID: 21664867.; Ravaud A., Barrios C.H., Alekseev B. et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as firstline therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2015;26(7):1378–84. DOI:10.1093/annonc/mdv170. PMID: 25851632.; Rini B.I., Bellmunt J., Clancy J. et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014;32(8):752–9. DOI:10.1200/JCO.2013.50.5305.; https://oncourology.abvpress.ru/oncur/article/view/687
-
5Academic Journal
Authors: I. N. D’yakov, S. K. Zyryanov, И. Н. Дьяков, С. К. Зырянов
Source: Cancer Urology; Том 12, № 4 (2016); 43-51 ; Онкоурология; Том 12, № 4 (2016); 43-51 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-4
Subject Terms: эверолимус, advanced renal cell carcinoma, target therapy, tyrosine kinase inhibitor, pazopanib, sunitinib, aksitinib, bevacizumab, interferon alfa, everolimus, распространенный почечноклеточный рак, таргетная терапия, ингибитор тирозинкиназ, пазопаниб, сунитиниб, акситиниб, бевацизумаб, интерферон альфа
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/640/598; Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России, 2016. 250 с. [Malignant tumors in Russia in 2014 (morbidity and fatality). Eds. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow: FGBU “Moskovskiy nauchno-issledovatel’skiy onkologicheskiy institut im. P.A. Gertsena” – filial FGBU “Natsional’nyy meditsinskiy issledovatel’skiy radiologicheskiy tsentr” Minzdrava Rossii, 2016. 250 p. (In Russ.)].; Алексеев Б.Я., Калпинский А.С. Эффективность применения таргетной терапии в гетерогенной популяции больных метастатическим раком почки. Онкоурология 2012; (3):37–42. [Alekseev B.Ya., Kalpinskiy A.S. Efficiency of targeted therapy used in the heterogeneous population of patients with metastatic kidney cancer. Onkourologiya = Oncourology 2012;(3):37–42. (In Russ.)].; Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74–108. PMID: 15761078.; Матвеев В.Б., Волкова М.И. Последовательная таргетная терапия при диссеминированном раке почки. Онкоурология 2013;(1):28–33. [Matveev V.B., Volkova M.I. Sequential targeted therapy for disseminated kidney cancer. Onkourologiya =Oncourology 2013;(1):28–33. (In Russ.)].; Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163(2): 408–17. PMID: 10647643.; Fojo A.T., Shen D.W., Mickley L.A. et al. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987;5(12):1922–7. PMID: 3681376.; Atzpodien J., Kirchner H., Illiger H.J. et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85(8):1130–6. PMID: 11710825. PMCID: PMC2375150. DOI:10.1054/bjoc.2001.2076.; Huland E., Heinzer H. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alphainterferon (leucocyte) and tamoxifen. Br J Cancer 2000;82(1):246–7. PMID: 10638997. PMCID: PMC2363186. DOI:10.1054/bjoc.1999.0952.; Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353(9146):14–7. PMID: 10023944.; Oliver R.T., Miller R.M., Mehta A., Barnett M.J. A phase II study of surveillance in patients with metastatic renal cell and assessment of response of such patients to therapy on progression. Mol Biother 1998;1(1):14–20. PMID: 3267368.; Vogelzang N.J., Priest E.R., Borden L. Spontaneous regression of hystologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up. J Urol 1992;148(4):1247–8. PMID: 1404646.; Atkins M.B., Regan M., McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10(18):6342S–6S. PMID: 15448028. DOI:10.1158/1078-0432.CCR-040029.; Fisher R.I., Rosenberg S.A., Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6 (Suppl 1):55–7. PMID: 10685660.; McDermott D.F., Regan M.M., Clark J.I. et al. Randomized phase III trial of highdose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23(1):133–41. PMID: 15625368. DOI:10.1200/JCO.2005.03.206.; Motzer R.J., Murphy B.A., Bacik J. et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18(16):2972–80. PMID: 10944130.; Negrier S., Escudier B., Lasset C. et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338(18):1272–8. PMID: 9562581. DOI:10.1056/NEJM199804303381805.; Yang J.C., Sherry R.M., Steinberg S.M. et al. Randomized study of high-dose and lowdose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21(16):3127–32. PMID: 12915604. PMCID: PMC2275327. DOI:10.1200/JCO.2003.02.122.; SEER. Program coding and staging manual 2007 Appendix C Part 6: C64.9–C80.9. 2008. Available at: http://seer.cancer.gov/tools/codingmanuals/.; Wahlgren T., Harmenberg U., Sandstrom P. et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008). Br J Cancer 2013;108(7):1541–9. PMID: 23531701. PMCID: PMC3629428. DOI:10.1038/bjc.2013.119.; Gnarra J.R., Tory K., Weng Y. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85–90. PMID: 7915601. DOI:10.1038/ng0594-85.; Iliopoulos O., Levy A.P., Jiang C. et al. Negative regulation of hypoxia-inducible genes by the von Hippel–Lindau protein. Proc Natl Acad Sci USA 1996;93(20):10595–9. PMID: 8855223. PMCID: PMC38198.; Maxwell P.H., Wiesener M.S., Chang G.W. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygendependent proteolysis. Nature 1999;399(6733):271–5. PMID: 10353251. DOI:10.1038/20459.; Na X., Wu G., Ryan C.K. et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxiainducible factor-1 alpha expression in renal cell carcinomas. J Urol 2003;170:588–92.; de Paulsen N., Brychzy A., Foumier M.C. et al. Role of transforming growth factor-alpha in von Hippel–Lindau (VHL)(–/–) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl AcadSci USA 2001;98(4):1387–92. PMID: 11171960. PMCID: PMC29266. DOI:10.1073/pnas.031587498.; Hutson T.E., Lesovoy V., Al-Shukri S. et al. Axitinib versus sorafenib as firstline therapy in patients with metastatic renal-cell carcinoma: a randomisedopenlabel phase III trial. Lancet Oncol 2013;14(13):1287–94. PMID: 24206640. DOI:10.1016/S1470-2045(13)70465-0.; Motzer R.J., Barrios C.H., Kim T.M. et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32(25):2765–72. PMID: 25049330. DOI:10.1200/JCO.2013.54.6911.; Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722—31. PMID: 23964934. DOI:10.1056/NEJMoa1303989.; Motzer R.J., Nosov D., Eisen T. et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a Phase III trial. J Clin Oncol 2013;31(30):3791–9. PMID: 24019545. DOI:10.1200/JCO.2012.47.4940.; Rini B.I., Bellmunt J., Clancy J. et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014;32(8):752–9. DOI:10.1200/JCO.2013.50.5305.; Ratain M.J., Eisen T., Stadler W.M. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505–12. PMID: 16636341. DOI:10.1200/JCO.2005.03.6723.; Escudier B., Bellmunt J., Negrier S. et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28(13):2144–50. PMID: 20368553. DOI:10.1200/JCO.2009.26.7849.; Rini B.I., Halabi S., Rosenberg J.E. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137–43. PMID: 20368558. PMCID: PMC2860433. DOI:10.1200/JCO.2009.26.5561.; Hurwitz H., Dowlati A., Savage S. et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol 2005;23:195.; Hutson T., Davis I., Machiels J. et al: Predictive and prognostic factors in phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. Ann Oncol 2008;19:187.; Abrams T.J., Lee L.B., Murray L.J. et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2(5):471–8. PMID: 12748309.; Mendel D.B., Laird A.D., Xin X. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and plateletderived growth factor receptors: determination of a pharmacokinetic/pharmacodynamics relationship. Clin Cancer Res 2003;9:327–37.; Rini B.I., Rixe O., Bukowski R.M. et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase II study of cytokinerefractory, metastatic renal cell cancer (RCC). J Clin Oncol 2005;23:4509.; Sonpavde G., Hutson T.E., Rini B.I. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 2008;17(5):741–8. PMID: 18447599. DOI:10.1517/13543784.17.5.741.; Flaherty K.T. Sorafenib in renal cell carcinoma. Clin Cancer Res 2007;13(2): 747s–52s. PMID: 17255304. DOI:10.1158/1078-0432.CCR-06-2063.; O’Farrell A.M., Abrams T.J., Yuen H.A. et al. SU11248 is a novel FLT-3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101(9):3597–605. PMID: 12531805. DOI:10.1182/blood-2002-07-2307.; Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115–24. PMID: 17215529. DOI:10.1056/NEJMoa065044.; Chang X., Zhang F., Liu T. et al. Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs. Oncotarget 2016;7(13):15801–10. PMID: 26908455. PMCID: PMC4941278. DOI:10.18632/oncotarget.7511.; Larkin J., Paine A., Foley G. et al. Firstline treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis. Expert Opin Pharmacother 2015;16(13):1915–27. PMID: 26194211. DOI:10.1517/14656566.2015.1058359.; Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of randomized Phase III trial. J Clin Oncol 2010;28(6):1061–8. PMID: 20100962. DOI:10.1200/JCO.2009.23.9764.; Rini B.I., Halabi S., Rosenberg J.E. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26(33):5422–8. РMID: 18936475. PMCID: PMC2651074. DOI:10.1200/JCO.2008.16.9847.; Bergmann L., Kube U., Doehn C. et al. Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study. BMC Cancer 2015;15:303. PMID: 25925846. PMCID: PMC4413536. DOI:10.1186/s12885-015-1309-7.; Buchler T., Bortlicek Z., Poprach A. et al. Efficacy of everolimus in second- and thirdline therapy for metastatic renal cell carcinoma: a registry-based analysis. Urol Oncol 2014;32(5):569–75. PMID: 24629497. DOI:10.1016/j.urolonc.2013.12.007.; Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18): 4256–65. PMID: 20549832. DOI:10.1002/cncr.25219.; Thiery-Vuillemin A., Theodore C., Jacobasch L. et al. Efficacy and safety of sequential use of everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab with or without interferon therapy: results from the european AVATOR study. Clin Genitourin Cancer 2015;13(3):231–8. PMID: 25456838. DOI:10.1016/j.clgc.2014.09.005.; Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase III trial. Lancet 2011;378(9807):1931–9. PMID: 22056247. DOI:10.1016/S0140-6736(11)61613-9.; Vogelzang N.J., Pal S.K., Signorovitch J.E. et al. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. Curr Med Res Opin 2016;32(4):741–7. PMID: 26744781. DOI:10.1185/03007995.2016.1140028.; Remak E., Charbonneau C., Negrier S. et al. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol 2008;26(24): 3996–4000. PMID: 18711190. DOI:10.1200/JCO.2007.13.2662.; Benedict A., Figlin R.A., Sandström P. et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int 2011;108(5): 665–72. PMID: 21265994. DOI:10.1111/j.1464-410X.2010.09957.x.; Ravasio R., Ortega C., Sabbatini R., Porta C. Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis. Clin Drug Investig 2011;31(7): 507–17. PMID: 21627339. DOI:10.2165/11590230-000000000-00000.; Delea T.E., Amdahl J., Diaz J. et al. Costeffectiveness of pazopanib versus sunitinib for renal cancer in the United States. J Manag Care Spec Pharm 2015;21(1):46–54, 54a–b. PMID: 25562772. DOI:10.18553/jmcp.2015.21.1.46.; Kilonzo M., Hislop J., Elders A. et al. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal. Pharmacoeconomics 2013;31(1):15–24. PMID: 23329590. DOI:10.1007/s40273-012-0006-5.; MacLean E.A., Sandin R., Mardekian J. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm 2015;21(9):841–3. PMID: 26308231. DOI:10.18553/jmcp.2015.21.9.841.; Villa G., Hernández-Pastor L.J. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain. BMC Cancer 2013;13:399. PMID: 24004638. PMCID: PMC3856525. DOI:10.1186/1471-2407-13-399.; Hansen R.N., Hackshaw M.D., Nagar S.P. et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Pharm 2015;21(1):37–44. PMID: 25562771. DOI:10.18553/jmcp.2015.21.1.37. Зырянов С.К., Фролов М.Ю., Дьяков И.Н. Клинико-экономическая оценка применения пазопаниба в терапии распространенного рака почки. Онкоурология 2016;12(1): 106–18. [Zyryanov S.K., Frolov M.Yu., D’yakov I.N. Clinical economic assessment of the use of pazopanib in the therapy of disseminated kidney cancer. Onkourologiya = Cancerurology 2016;12(1):106–18. (In Russ.)]. DOI: 10.17 650/1726-9776-2016-12-1-106-114.; Perrin A., Sherman S., Pal S. et al. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. J Med Econ 2015;18(3):200–9. PMID: 25422989. DOI:10.3111/13696998.2014.985789.; Casciano R., Chulikavit M., Di Lorenzo G. et al. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. Value Health 2011;14(6):846–51. PMID: 21914504. DOI:10.1016/j.jval.2011.04.008.; Petrou P. Cost-effectiveness analysis of axitinib through a probabilistic decision model. Expert Opin Pharmacother 2015;16(8):1233–43. PMID: 25958963. DOI:10.1517/14656566.2015.1039982.; https://oncourology.abvpress.ru/oncur/article/view/640